|
|
|
|
Vol. 61, Issue 4, 885-891, April 2002
Molecular Neurobiology Branch, National Institute on Drug
Abuse-Intramural Research Program, National Institutes of Health,
Baltimore, Maryland
Cocaine's blockade of dopamine reuptake by brain dopamine transporters
(DAT) is a central feature of current understanding of cocaine reward
and addiction. Empirical screening of small-molecule chemical libraries
has thus far failed to provide successful cocaine blockers that allow
dopamine reuptake in the presence of cocaine and provide cocaine
"antagonism". We have approached this problem by assessing
expression, dopamine uptake, and cocaine analog affinities of 56 DAT
mutants in residues located in or near transmembrane domains likely to
play significant roles in cocaine recognition and dopamine uptake. A
phenylalanine-to-alanine mutant in putative DAT transmembrane domain 3, F154A, retains normal dopamine uptake, lowers cocaine affinity 10-fold,
and reduces cocaine stereospecificity. Such mutants provide windows
into DAT structures that could serve as targets for selective cocaine
blockers and document how combined strategies of mutagenesis and small
molecule screening may improve our abilities to identify and design
compounds with such selective properties.
This article has been cited by other articles:
![]() |
C. J. Loland, C. Granas, J. A. Javitch, and U. Gether Identification of Intracellular Residues in the Dopamine Transporter Critical for Regulation of Transporter Conformation and Cocaine Binding J. Biol. Chem., January 30, 2004; 279(5): 3228 - 3238. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu and H. H. Gu Cocaine Affinity Decreased by Mutations of Aromatic Residue Phenylalanine 105 in the Transmembrane Domain 2 of Dopamine Transporter Mol. Pharmacol., March 1, 2003; 63(3): 653 - 658. [Abstract] [Full Text] [PDF] |
||||